28 May 2014Big Pharma

EPO upholds Copaxone patent

Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
15 October 2018   The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone 40mg/mL treatment are invalid.

More on this story

Americas
15 October 2018   The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone 40mg/mL treatment are invalid.

More on this story

Americas
15 October 2018   The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone 40mg/mL treatment are invalid.